Cambridge Healthtech Institute’s 8th Annual

Antibodies Against Membrane Protein Targets – Part 2

Antigen Engineering, Antibody Discovery, and Research Challenges

 

As the pharmaceutical and biotech industries increasingly shift attention to biologics, much more attention is being paid to the prospect of developing membrane-bound targets for biotherapeutics. For the large GPCR and ion channel target classes, biologics offer improved selectivity, an alternative for targets with known function that have not been amenable to small molecule drugs, and the potential for using antibodies for the targeted delivery of therapeutics. However, for the field to advance, fundamental challenges in optimizing antigen quality and presentation, discovery methodologies, protein engineering and target identification must be resolved. This two-part meeting provides a forum in which discovery biologists and protein engineers can come together to discuss next generation strategies and technologies that will allow biologic drugs for these target families to advance into the clinic and beyond.

Preliminary Agenda

ANTIGEN DESIGN AND ENGINEERING

Talk Title to be Announced

Janice Robertson, PhD, Assistant Professor, Biochemistry and Molecular Biophysics, Washington University in St. Louis

Membrane Proteins without Membranes: Designed Resurfacing for Improved Solubility

Jeffery Saven, PhD, Professor, Chemistry, University of Pennsylvania

Emerging Technologies for Antigen Preparation and Stability

Osvaldo Cruz-Rodriguez, PhD, Senior Scientist, AbbVie

Using NGS and Virus-like Particles to Develop Antibodies Against Integral Membrane Proteins

Mart Ustav Jr., PhD, Postdoctoral Fellow, Sidhu Lab, University of Toronto, Canada

Synthetic Membranes and Membrane Platforms that Mimic Lipid Bilayers to Support Membrane Proteins

Hongjun Liang, PhD, Associate Professor, Cell Physiology & Molecular Biophysics, Texas Tech University

Talk Title to be Announced

ANTIBODY DISCOVERY

Discovering Therapeutic Antibodies to Challenging Multipass Transmembrane Targets

Meredith Hazen, PhD, Senior Scientific Researcher, Genentech

Structure- and Sequence-Based Design of Synthetic Single-Domain Antibody Libraries

Alex Sevy, PhD, Associate Scientist, Merck

Structural Design of Engineered Protein Constructs to Enable Antibody Discovery

Abhishek Datta, PhD, Director, Antibody Discovery & Engineering, Scholar Rock

Strategies to Focus Phage Display Output on Specific Target Epitopes

Tadas Panavas, PhD, Senior Principal Scientist, Boehringer Ingelheim

Talk Title to be Announced

Zachary Britton, PhD, Scientist, Antibody Discovery, AstraZeneca

Presentation to be Announced

R&D TOOLS AND WORKFLOWS

Structure of CD20 in Complex with the Therapeutic Monoclonal Antibody Rituximab

Lionel Rougé, PhD, Principal Scientific Researcher, Genentech

High-Throughput Discovery of Antibodies to Multi-Spanning Membrane Proteins

Noel Pauli, PhD, Senior Scientist, Adimab LLC

Next Generation Strategies for Antibody Discovery to Membrane Proteins

Brian Booth, PhD, Senior Scientist, Drug Discovery, Visterra

Talk Title to be Announced

Anna Yarilina, PhD, Senior Scientist, AbbVie Bioresearch Center


Please click here to return to the agenda for Antibodies Against Membrane Protein Targets – Part 1




For more details on the conference, please contact:
Kent Simmons

Senior Conference Director

Cambridge Healthtech Institute

Phone: (+1) 207-869-9199
Email: ksimmons@healthtech.com

 

For partnering and sponsorship information, please contact:
Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286
Email: reymael@healthtech.com